Home > Resources > Whitepapers > How Does Pharma Learn To Speak “Patient”?

How Does Pharma Learn To Speak “Patient”?

July 11, 2019

This eBook takes readers through an example of discourse analysis of a patient community on Inspire. In the process, author Kathryn Ticknor demonstrates how the language of patients is a different language from “medicalese,” the language of medicine. Her insights are a first step in learning how to speak “patient.”

Spotlight

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. (Nasdaq:RETA), is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

OTHER WHITEPAPERS

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Read More

PHARMACEUTICAL KEY ACCOUNT MANAGEMENT: HARNESSING SALES EXPERTISE TO DEVELOP UNIFIED STAKEHOLDER RELATIONSHIPS

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

Read More

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Read More

Non-Clinical Testing Considerations: Drugs vs Devices

whitePaper | November 8, 2022

While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most important difference is that medical devices do not achieve their principal action by pharmacological means.

Read More

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

Read More

Securing the modern pharmaceutical supply chain

whitePaper | April 22, 2022

Members of the Health-ISAC community have produced a security framework for the pharmaceutical supply chain comprising this CISO guide.

Read More

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Read More

PHARMACEUTICAL KEY ACCOUNT MANAGEMENT: HARNESSING SALES EXPERTISE TO DEVELOP UNIFIED STAKEHOLDER RELATIONSHIPS

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

Read More

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Read More

Non-Clinical Testing Considerations: Drugs vs Devices

whitePaper | November 8, 2022

While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most important difference is that medical devices do not achieve their principal action by pharmacological means.

Read More

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

Read More

Securing the modern pharmaceutical supply chain

whitePaper | April 22, 2022

Members of the Health-ISAC community have produced a security framework for the pharmaceutical supply chain comprising this CISO guide.

Read More

More Whitepapers

Spotlight

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. (Nasdaq:RETA), is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

Events